Compare Goodyear Tire & Rubber Co (GT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs Novartis AG — how do they compare? Goodyear Tire & Rubber Co trades at $6.76 (market cap $1.94B), while Novartis AG trades at $150.91 (market cap $287.66B). The key difference: Novartis AG is far larger — about 148.3× Goodyear Tire & Rubber Co's market cap, and Novartis AG pays a 3.14% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals.
| GT | NVS | |
|---|---|---|
Market Cap | $1.94B | $287.66B |
Sector | Consumer Cyclical | Health |
52-Week High | $11.54 | $168.62 |
52-Week Low | $5.58 | $113.50 |
Enterprise Value | $9.25B | $327.68B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GT trades at $7.18, up 7.81% today, with a bullish technical signal and moving average alignment. The stock shows attractive valuation ratios (P/E 4.69, P/B 0.64) but faces profitability challenges, with a net income margin of -11.64% in 2025. Recent news includes a shift to the S&P SmallCap 600 and a $1.05 billion senior notes offering. Q1 2026 earnings beat estimates, yet revenue trends are declining.
Outlook: Deep value metrics and analyst consensus target of $8.75 suggest upside, but persistent net losses, high debt, and competitive pressures pose significant risks. Investors should weigh low valuation against operational headwinds and macroeconomic sensitivity.
NVS trades at $152.51, up 1.43% today, with a bearish technical signal despite strong profitability metrics including a 75.38% gross margin and 35.21% ROE. Recent earnings show mixed results, missing Q1 2026 estimates but beating Q4 2025. The company is actively expanding its oncology pipeline through acquisitions like Myricx Bio for up to $1.5 billion (Reuters, 2026-07-06).
The outlook is balanced; robust cash flow and high margins support growth, but rising debt-to-asset ratios and cautious analyst consensus (68% hold) indicate near-term headwinds. Key risks include execution of pipeline developments and competitive pressures in pharmaceuticals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
